This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the formula

or a pharmaceutically acceptable salt thereof, wherein

(a) R_9 is selected from the group consisting of H, thienyl, furanyl, pyrrolyl, phenyl, substituted phenyl, pyridinyl, substituted pyridinyl, naphthyl, benzo[b]thien-2-yl, 2-benzofuranyl, pyrimidine and 2,4-(bismethoxyphenyl)-5-pyrimidinyl,

said substituted phenyl having the formula



wherein (i) R_{12} is H, OH, lower alkylthio, alkoxy, alkylamine, dialkylamine, halogen-substituted lower alkyl, halogen substituted lower alkoxy, cyano, cyanoalkyl, phenyl, phenylalkoxy or substituted piperazinyl, N-(t-butoxy)carbamylalkyl, (ii) each R_{13} is independently H, NO_2, alkoxy, alkylamino, dialkylamino, halogen-substituted lower alkyl, halogen-substituted lower alkoxy or phenyl, and (iii) each R_{14} is independently H, alkoxy, phenyloxy or phenylalkoxy;

(b) R_{10} is selected from the group consisting of cyanoalkyl, alkylamino, dialkylamino, hydroxy-substituted alkylamino and hydroxy-substituted dialkylamino; and

(c) R_{11} is H or lower alkyl.

2. (Original) The pharmaceutical composition of claim 1, wherein R_9 is substituted phenyl.

3. (Original) The pharmaceutical composition of claim 1, wherein R_{11} is H and R_{10} is dialkylamino or hydroxy-substituted dialkylamino.

4. (Original) The pharmaceutical composition of claim 1, wherein the compound is N1,N1-dimethyl-N4-[6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]-1,4-benzenediamine.

5. (Original) The pharmaceutical composition of claim 1, wherein the compound is N1-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N4,N4-dimethyl-1,4-benzenediamine.

6. (Original) The pharmaceutical composition of claim 1, wherein the compound is N1-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]-N4,N4-dimethyl-1,4-benzenediamine.

7. (Original) The pharmaceutical composition of claim 1, wherein the compound is 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]-ethanol.

8. (Original) The pharmaceutical composition of claim 1, wherein the compound is 2-[[4-[(6-benzo[b]thien-2-yl-4-pyrimidinyl)amino]phenyl]ethylamino]-ethanol.

9. (Original) The pharmaceutical composition of claim 1, wherein the compound is 2-[ethyl[4-[[6-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenyl] amino]-ethanol.

10. (Original) The pharmaceutical composition of claim 1, wherein the compound is of the formula



11. Previously canceled.

12. (Currently amended) A method for reducing ischemic death in a cell population comprising contacting the cell population with an ~~a prophylactically effective~~ amount of the compound of claim 1 effective to reduce the ischemic death in the cell population.

13. Previously canceled.

14. (Original) The method of claim 12, wherein the cell population comprises a cell selected from the group consisting of a neuronal cell, a glial cell, a cardiac cell, a lymphocyte, a macrophage and a fibroblast.

15. Previously canceled.

16. (Currently amended) A method of reducing death in a cell population comprising neuronal cells in response to a traumatic event comprising contacting the neuronal cells with ~~a prophylactically effective amount of~~ the compound contained in the

pharmaceutical composition of claim 1 prior to, during, or within a suitable time period following the traumatic event, wherein the neuronal cells are contacted with an amount of the compound effective to reduce the death in the cell population.

17. Previously canceled.

18. (Original) The method of claim 12 wherein the contacting is performed *in vitro*.

19. (Original) The method of claim 14, wherein the contacting is performed *in vitro*.

20. (Original) The method of claim 12 , wherein the contacting is performed *ex vivo*.

21. (Original) The method of claim 14, wherein the contacting is performed *ex vivo*.

22. (Original) The method of claim 12 , wherein the contacting is performed *in vivo*.

23. (Original) The method of claim 14, wherein the contacting is performed *in vivo*.

24. (Currently amended) A method of reducing neuronal cell death in response to a traumatic event in a subject, comprising administering to the subject a ~~prophylactically effective amount of~~ the pharmaceutical composition of claim 1 prior to, during, or following the traumatic event, wherein the subject is administered an amount of the compound effective to reduce the neuronal cell death.

25. Previously canceled.

26. (Original) The method of claim 24, wherein the subject is a human.

27. (Original) The method of claim 24, wherein the traumatic event is selected from the group consisting of a medical disorder, a physical trauma, a chemical trauma and a biological trauma.

28. (Original) The method of claim 24, wherein the pharmaceutical composition is administered prior to the traumatic event.

29. (Original) The method of claim 24, wherein the pharmaceutical composition is administered during the traumatic event.

30. (Original) The method of claim 24, wherein the pharmaceutical composition is administered subsequent to the traumatic event.

31 – 35. Previously canceled.

36. Currently canceled.

37. Previously canceled.

38. Currently canceled.

39. Currently canceled.

40 - 66. Previously canceled.